AR,darolutamide + goserelin+pertuzumab/trastuzumab Clinical Trials

1 actively recruiting trial

Also known as: Cohort 10 (HER2+/AR+, darolutamide + goserelin + pertuzumab + trastuzumab)

Pipeline

Phase 2: 1

Top Sponsors

Peking Union Medical College1

Indications

Precision Therapy1
Salivary Gland Carcinoma1
Cancer1

Other1 trial

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.